197A — TAUNS Laboratories Share Price
Last trade - 00:00- ¥51bn
- ¥50bn
- ¥16bn
- 26
- 42
- 50
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.08 | ||
| Price to Tang. Book | 4.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.71 | ||
| EV to EBITDA | 7.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 28.12% | ||
| Return on Equity | 28.7% | ||
| Operating Margin | 29.78% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | n/a | n/a | n/a | 17,456.99 | 15,673.1 | n/a | n/a | -10.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -48.72 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 14th, 2016
- Public Since
- June 20th, 2024
- No. of Employees
- 272
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 100,000,000
- Address
- 761-1, Kamishima, IZUNOKUNI-SHI, 410-2325
- Web
- https://www.tauns.co.jp/
- Phone
- +81 558768181
- Auditors
- Ernst & Young ShinNihon LLC
Similar to 197A
Alfresa Holdings
Tokyo Stock Exchange
Asahi Intecc Co
Tokyo Stock Exchange
Aso International
Tokyo Stock Exchange
As One
Tokyo Stock Exchange
Atect
Tokyo Stock Exchange
FAQ
As of Today at 11:38 UTC, shares in TAUNS Laboratories are trading at ¥425. This share price information is delayed by 15 minutes.
Shares in TAUNS Laboratories last closed at ¥425 and the price had moved by over the past 365 days. In terms of relative price strength the TAUNS Laboratories share price has matched the Nikkei 225 Index by over the past year.
There is no consensus recommendation for this security.
TAUNS Laboratories does not currently pay a dividend.
TAUNS Laboratories does not currently pay a dividend.
TAUNS Laboratories does not currently pay a dividend.
To buy shares in TAUNS Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥425, shares in TAUNS Laboratories had a market capitalisation of ¥43bn.
Here are the trading details for TAUNS Laboratories:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 197A
Based on an overall assessment of its quality, value and momentum TAUNS Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TAUNS Laboratories. Over the past six months, its share price has matched the Nikkei 225 Index by .
As of the last closing price of ¥425, shares in TAUNS Laboratories were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TAUNS Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥425.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on TAUNS Laboratories' directors